Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
173 stopped studies mapped to Malignant Biliary Tract Neoplasm and descendants · 92% state a reason
Over the 173 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06199882 | SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma | Phase 2 | suspended | Jan 10, 2024 | Zhejiang Cancer Hospital | Patient recruitment difficulties | Enrollment / accrual |
| NCT04003896 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | Phase 2 | terminated | Jul 1, 2019 | Milton S. Hershey Medical Center | The manufacturer and funder Eli Lilly requested to terminate the study | Drug supply |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | Phase 2 | terminated | Aug 18, 2021 | CSPC Ouyi Pharmaceutical Co., Ltd. | Internal strategy change. Not related to safety concerns. | Safety / toxicity |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | N/A | withdrawn | Oct 14, 2020 | Medical University of Graz | Covid19 Pandemia | COVID-19 / pandemic |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2… | Phase 3 | terminated | Dec 12, 2018 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development… | Safety / toxicity |
| NCT04088188 | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of… | Phase 1 | terminated | Sep 12, 2019 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT02452970 | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration…(EPIC) | Phase 2 | terminated | May 25, 2015 | EpicentRx, Inc. | Poor enrollment and adverse event experiences in the limited population | Safety / toxicity |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated… | — | withdrawn | Mar 23, 2022 | Geneplus-Beijing Co. Ltd. | No participants were enrolled | Enrollment / accrual |
| NCT03291899 | Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers(FBI-TRAC) | Phase 2 | terminated | Sep 25, 2017 | King Faisal Specialist Hospital & Research Center | poor accrual | Enrollment / accrual |
| NCT00320918 | Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan,… | — | terminated | May 3, 2006 | University of New Mexico | This was a Chart Review only and was entered in the system in error. | Other (stated, no rule matched) |
| NCT05514912 | Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without… | Phase 2 | withdrawn | Aug 25, 2022 | Emory University | PI has decided to terminate this study due to study supporter pulling support on this study. | Other (stated, no rule matched) |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With… | Phase 2 / Phase 3 | terminated | Aug 26, 2019 | EMD Serono Research & Development Institute, Inc. | Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Sponsor… | Sponsor / business decision |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With…(RELEASE) | Phase 2 | terminated | Sep 23, 2019 | PCI Biotech AS | Recent results from a Phase 3 study are expected to change the standard of care for patients with… | Other (stated, no rule matched) |
| NCT04566133 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy… | Phase 2 | terminated | Sep 28, 2020 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT05510427 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The… | Phase 1 | withdrawn | Aug 22, 2022 | M.D. Anderson Cancer Center | Per PI's request | Other (stated, no rule matched) |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT00658593 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic… | Phase 3 | terminated | Apr 15, 2008 | NCIC Clinical Trials Group | due to poor accrual | Enrollment / accrual |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | Phase 2 | terminated | May 30, 2014 | QED Therapeutics, a BridgeBio company | The study was terminated early due to limited efficacy in Cohorts 2 and 3 (exploratory endpoints).… | Safety / toxicity |
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | — | terminated | Mar 10, 2006 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced… | Phase 3 | terminated | Nov 15, 2019 | NuCana plc | A pre-planned futility analysis concluded that NUC-1031 plus cisplatin was unlikely to achieve its… | Efficacy / futility |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT03790111 | A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With…(TELE-ABC) | Phase 2 | terminated | Dec 31, 2018 | TerSera Therapeutics LLC | Did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis | Other (stated, no rule matched) |
| NCT04784520 | A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer | Phase 2 | terminated | Mar 5, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The primary endpoint did not meet expectation. | Other (stated, no rule matched) |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT04076761 | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma(MOCHA) | Phase 2 | terminated | Sep 3, 2019 | Sunnybrook Health Sciences Centre | Lack of Funding | Funding |
| NCT04304781 | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer | Phase 1 | terminated | Mar 11, 2020 | Danielle Kim Turgeon | Terminated due to lack of dimer. | Other (stated, no rule matched) |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT03353181 | Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar…(ENBD) | N/A | withdrawn | Nov 27, 2017 | Changhai Hospital | Failure to recruit patients | Enrollment / accrual |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic… | Phase 1 | terminated | Feb 2, 2012 | Washington University School of Medicine | Equipment that was used in the study was discontinued | Other (stated, no rule matched) |
| NCT04717687 | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating…(HOPE) | N/A | withdrawn | Jan 22, 2021 | Poitiers University Hospital | No enrollment | Enrollment / accrual |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase 2 | withdrawn | May 20, 2021 | Walid Shaib, MD | Funder decision | Other (stated, no rule matched) |
| NCT03110510 | FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were… | Phase 2 | withdrawn | Apr 12, 2017 | Samsung Medical Center | institution problem | Other (stated, no rule matched) |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy… | Phase 2 | withdrawn | Sep 14, 2020 | Samsung Medical Center | problem of sponsor | Other (stated, no rule matched) |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | Phase 2 | terminated | Jan 27, 2021 | AIO-Studien-gGmbH | Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine… | Enrollment / accrual |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | Phase 1 | withdrawn | Jul 21, 2020 | Jordan Kharofa | Difficulty accruing | Enrollment / accrual |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment… | Phase 2 | withdrawn | Aug 25, 2021 | Fudan University | Repeat registration | Other (stated, no rule matched) |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Phase 2 | terminated | Dec 1, 2020 | American University of Beirut Medical Center | pharma company decision to withdraw the financial and IMP support | Funding |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab… | Phase 2 | terminated | Dec 5, 2016 | Aiwu Ruth He, MD | Manufacturer discontinued Sylatron | Drug supply |
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | N/A | withdrawn | Aug 13, 2020 | Michael Lidsky, M.D. | No subjects enrolled due to availability of device commercially. | Enrollment / accrual |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic… | Phase 2 | withdrawn | Jul 21, 2020 | Jiangsu HengRui Medicine Co., Ltd. | It is difficult to screening subject | Other (stated, no rule matched) |
| NCT03419247 | Molecular Profiling of Advanced Biliary Tract Cancers | N/A | withdrawn | Feb 1, 2018 | University Health Network, Toronto | Study was not activated | Other (stated, no rule matched) |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | N/A | withdrawn | May 27, 2020 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | Low accrual rate | Enrollment / accrual |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | Phase 2 | withdrawn | May 22, 2020 | Sun Yat-sen University | no patient enrolled | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 15, 2024source: clinicaltrials